new version V2017

Ipilimumab immune checkpoint inhibition
Description Results

MDX-010 - MDX010 - DX 010 - Yervoy - MDX-CTLA-4      

  • Group by...

pdf
TrialStudied treatmentControl treatmentpatientsROBResultNCT

lung cancer (metastatic)

phase 2 (phased ipilimumab), 2012ipilimumab + chemotherapyplacebo + chemotherapy -
Reck, 2016ipilimumab + chemotherapyplacebo + chemotherapySCLC - NCT01450761
Govindan, 2017ipilimumab + chemotherapyplacebo + chemotherapy1L Low risk of bias NegativeNCT01285609

melanoma

Hodi (ipi alone), 2010ipilimumab 3 mg/kggp1002L Risk of bias SuggestingNCT00094653
Hodi (ipi + gp100), 2010ipi + gp100gp1002L Risk of bias SuggestingNCT00094653
Robert, 2011ipilimumab + dacarbazinedacarbazine1L Low risk of bias ConclusiveNCT00324155
EORTC 18071 (Eggermont), 2015ipilimumabplaceboadjuvant Low risk of bias Conclusive NCT00636168



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons